An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health

• Nifurtimox (BAYA2502) (Drug): At least 1 dose of nifurtimox

Primary outcomes

• Major Congenital Malformations (birth defects) [Up to pregnancy week 40]: 1. any major structural defect diagnosed with signs/symptoms, using the selected major congenital anomalies list extracted from the Birth defects surveillance: a manual, CDC. 2. on a case-by-case basis, through evaluator review and agreement from external advisors (if required), any structural defect (that satisfy criterion 1 or 2) detected in the prenatal evaluation of a pregnancy or in the gross or pathologic examination of an abortus, fetus, or deceased infant will be included, if available, to increase the sensitivity of pregnancy study monitoring

Secondary outcomes

• Events of Interest in Neonates and Infants through 12 Months of Age: Hospitalizations for serious illness [Up to 12 months of age]
• Events of Interest in Neonates and Infants through 12 Months of Age: Medications [Up to 12 months of age]
• Events of Interest in Neonates and Infants through 12 Months of Age: Growth and development milestones [Up to 12 months of age]: Apgar Scale, CDC Growth Calculators, Cognitive Checklists, ASD (autism spectrum disorder) Tool
• Events of Interest in Neonates and Infants through 12 Months of Age: Neonatal or infant mortality [Up to 12 months of age]
• Maternal Complications: Premature rupture of membranes (PROM) [Up to pregnancy week 40]
• Maternal Complications: Preeclampsia [Up to pregnancy week 40]
• Maternal Complications: Severe pregnancy-induced hypertension (PIH) [Up to pregnancy week 40]
• Maternal Complications: Proteinuria [Up to pregnancy week 40]
• Maternal Complications: Gestational diabetes [Up to pregnancy week 40]
• Maternal Complications: Measures of fetal growth deficiency (small for gestational age) [Up to pregnancy week 40]
• Spontaneous abortion [Up to 20 weeks]: Any loss of a fetus due to natural causes less than 20 weeks gestation as a spontaneous abortion (WHO/CDC/ICBDSR, 2014). If available, data from gross or pathological examination of the abortus or fetus will be evaluated for structural defects.
• Elective/Induced abortion [Up to pregnancy week 40]: Elective or induced abortion is the termination of pregnancy through medical or surgical procedures (ACOG, 2014) (WHO, 2014) If available, data from gross or pathological examination of the abortus or fetus will be evaluated for structural defects.
• Fetal death/Still birth [More than 20 weeks gestation or weighing less than 500 grams]: Fetal death or stillbirth refers to fetuses born dead at > 20 weeks gestation or weighing > 500 grams. Fetal death occurring > 20 weeks but less than 28 weeks gestation is considered an early fetal loss. Fetal death occurring > 28 weeks is considered a late fetal loss (ACOG, 2014). If available, data from gross or pathological examination of the abortus or fetus will be evaluated for structural defects. • The study will make the final classification between fetal death/still birth and spontaneous abortion based on gestational age and weight. If these parameters are not available, the study will accept the classification indicated by the HCP.
• Preterm delivery [Prior to 37 completed weeks of gestation]: Births delivered prior to 37 completed weeks of gestation per 100 births. Gestational age is based on the obstetric estimate of gestation (CDC).
• Live Birth [Up to pregnancy week 40]: A live birth refers to a complete expulsion from its mother of a surviving neonate breathing or showing any evidence of life such as a heartbeat, umbilical cord pulsation, or definite movement of voluntary muscles, whether the umbilical cord has been cut or the placenta is attached (WHO, 2014).
• Ectopic or Molar Pregnancy [Up to pregnancy week 40]: Any reported ectopic or molar pregnancy will be sub-classified in the respective pregnancy outcome including induced abortion, live birth, or spontaneous pregnancy loss. CDC National Center for Health Statistics surveillance system (NCHS, 2004 ).

Sex: Female

Inclusion Criteria:

* Females exposed to at least 1 dose of nifurtimox at any time during pregnancy (i.e., from the first day of the last menstrual period / time of conception to pregnancy outcome).
* Written informed consent (for adolescents under the age of majority, written informed assent by the pregnant minor (where applicable) and written informed consent by the parent/legal guardian).

Exclusion Criteria:

* None